Gilead Sciences
GILD
$124.87
+0.90%
Gilead Sciences is a leading biopharmaceutical company focused on developing and commercializing therapies for life-threatening infectious diseases, with a core portfolio in HIV and viral hepatitis. The company has established a distinct competitive identity as a market leader in antiviral therapies while aggressively transforming itself into a major oncology player through strategic acquisitions like Kite Pharma (CAR-T) and Immunomedics (Trodelvy). The current investor narrative is dominated by the company's aggressive M&A strategy to build its oncology and immunology pipelines, highlighted by recent multi-billion dollar deals for Arcellx and Tubulis, which is a calculated bet on long-term growth but also introduces integration risks and near-term financial headwinds.…
GILD
Gilead Sciences
$124.87
Related headlines
Investment Opinion: Should I buy GILD Today?
Rating & Thesis: Gilead Sciences is rated a Hold. The core thesis is that the stock presents a compelling long-term value proposition based on its cash-generative HIV business and strategic oncology pivot, but near-term technical weakness, integration risks, and lack of a clear catalyst warrant patience. This aligns with the unanimous 'Buy' analyst sentiment but acknowledges the stock's severe underperformance relative to the market.
Supporting Evidence: The Hold rating is supported by four key data points: 1) The attractive forward P/E of 12.80x, which discounts expected EPS growth to $13.14; 2) Robust profitability metrics, including a TTM net margin of 28.90% and TTM free cash flow of $9.46 billion; 3) A solid balance sheet with a current ratio of 1.68, providing flexibility; and 4) The stock's defensive low-beta profile (0.33), which may appeal in a market downturn. However, these are counterbalanced by the 9.80% three-month price decline and revenue growth of just 4.7% YoY in Q4 2025.
Risks & Conditions: The two biggest risks to the thesis are further clinical pipeline failures that delay the oncology growth narrative, and an inability to stabilize the stock's technical downtrend. This Hold would upgrade to a Buy if the forward P/E compresses further towards 11x on sustained earnings delivery, or if the stock establishes a firm base above its 52-week low and shows relative strength. It would downgrade to a Sell if quarterly revenue growth decelerates below 2%, or if the debt-to-equity ratio rises above 1.5 due to more dilutive acquisitions. Based on its forward P/E relative to its own history and stable earnings, the stock is currently fairly valued, pricing in both its strengths and its significant execution challenges.
Sign up to view all
GILD 12-Month Price Forecast
The AI assessment is neutral with medium confidence. Gilead's fundamentals are strong, with exceptional cash flow and a reasonable valuation, but the stock is clearly in a penalty box due to its aggressive and costly strategic shift. The base case (60% probability) of range-bound trading is most likely, as the market awaits proof that the oncology acquisitions will deliver. The stance would upgrade to bullish on a confirmed technical reversal above $140 coupled with evidence of successful pipeline progression. It would turn bearish if the stock breaks below $104.46 (the 52-week low), signaling a failure of the long-term support level and potentially triggering a deeper re-rating.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Gilead Sciences's 12-month outlook, with a consensus price target around $162.33 and implied upside of +30.0% versus the current price.
Average Target
$162.33
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$100 - $162
Analyst target range
Analyst coverage for Gilead is robust, with 11 analysts providing estimates, and recent institutional ratings from firms like Needham, Truist, and UBS are unanimously positive, all maintaining Buy or Overweight ratings, indicating strong bullish sentiment. The consensus revenue estimate for the next period is $38.89 billion, with a high estimate of $40.29 billion and a low of $37.84 billion, while the EPS consensus is $13.14, ranging from $12.67 to $13.75, though a specific average price target is not provided in the data to calculate implied upside. The target range and recent rating actions signal high conviction in the company's strategy, with the high-end estimates likely banking on successful integration of acquisitions and pipeline catalysts, while the low end may reflect concerns over competitive pressures or clinical setbacks, as evidenced by the recent termination of a Trodelvy-Keytruda lung cancer trial.
Bulls vs Bears: GILD Investment Factors
The investment debate for Gilead Sciences centers on a clash between its strong fundamental foundation and its challenging near-term technical and execution outlook. The bull case, supported by unanimous analyst ratings, is anchored in the company's robust profitability, massive cash generation, and a forward P/E of 12.8x that prices in significant earnings growth from its strategic oncology build-out. The bear case highlights the stock's severe technical breakdown, heavy reliance on a mature HIV business, and the high cost and risk associated with its acquisition-heavy transformation. Currently, the bearish evidence from price action and momentum is stronger, as the stock has dramatically underperformed the market despite its solid finances. The single most important tension is whether Gilead's expensive and aggressive M&A strategy will successfully deliver the promised long-term growth in oncology to justify its current valuation, or if integration challenges and pipeline setbacks will continue to weigh on investor sentiment and the stock price.
Bullish
- Strong Profitability and Cash Flow: Gilead generates robust free cash flow of $9.46 billion TTM, supporting its aggressive M&A strategy and shareholder returns. The company maintains a high gross margin of 86.84% (Q4 2025) and a trailing net margin of 28.90%, indicating efficient operations and pricing power in its core HIV franchise.
- Attractive Forward Valuation: The stock trades at a forward P/E of 12.80x, a significant discount to its trailing P/E of 17.94x, reflecting analyst expectations for EPS to grow from $0.06 to $13.14. This forward multiple suggests the market is not pricing in excessive optimism for the company's growth and acquisition strategy.
- Unanimous Analyst Bullish Sentiment: All 11 covering analysts maintain Buy or Overweight ratings, signaling high institutional conviction. The consensus EPS estimate of $13.14 for the forward period implies strong earnings growth, underpinned by the company's strategic pivot into oncology.
- Solid Balance Sheet and Defensive Profile: With a manageable debt-to-equity ratio of 1.08 and a strong current ratio of 1.68, Gilead can fund acquisitions without excessive financial strain. The stock's low beta of 0.33 indicates it has been a defensive, low-volatility holding relative to the market, which fell sharply over the past three months while GILD declined less.
Bearish
- Pronounced Technical Downtrend and Weakness: The stock has declined 9.80% over three months and 5.16% over one month, severely underperforming the SPY's gains of 15.14% and 0.74% respectively. Trading at $123.76, it is just 37% above its 52-week low of $104.46, signaling a significant loss of momentum and potential trend reversal.
- High Dependence on Mature HIV Business: The HIV segment generated $5.8 billion in Q4 2025 sales, representing approximately 73% of total revenue. This heavy concentration creates vulnerability to pricing pressure, generics, or pipeline setbacks in newer growth areas like oncology, which contributed just $1.01 billion combined (Cell Therapy and Trodelvy).
- Inconsistent Profitability and High Acquisition Costs: Quarterly net income has been volatile, ranging from $3.05 billion in Q3 2025 to a loss of -$4.17 billion in Q1 2024. The aggressive M&A strategy, including recent deals for Arcellx ($7.8B) and Tubulis ($3.15B), introduces near-term financial headwinds, integration risks, and dilution without immediate earnings contributions.
- Pipeline Setbacks and Clinical Trial Risks: The recent termination of the Trodelvy-Keytruda lung cancer trial with Merck highlights the high-risk nature of drug development. Such setbacks delay the monetization of acquired assets and increase uncertainty around the long-term success of the company's expensive pivot into oncology.
GILD Technical Analysis
The stock is in a pronounced downtrend from its recent highs, having declined 9.80% over the past three months and 5.16% over the past month, significantly underperforming the broader market which gained 15.14% and 0.74% over the same periods, respectively. Despite the recent weakness, the stock's 1-year price change of 14.59% indicates a longer-term uptrend, though it is now trading near the lower end of its 52-week range, with the current price of $123.76 sitting just 37% above its 52-week low of $104.46 and 21% below its high of $157.29, suggesting a potential value opportunity after a sharp correction. Recent momentum is decisively negative, with the 1-month decline of 5.16% and 3-month decline of 9.80% sharply diverging from the positive 1-year trend, signaling a significant loss of momentum and potential trend reversal or a deep pullback within a longer-term uptrend, exacerbated by a very low beta of 0.33 indicating the stock has been far less volatile than the market during this sell-off. Key technical support is at the 52-week low of $104.46, while resistance is at the 52-week high of $157.29; a breakdown below $104.46 would signal a complete failure of the prior uptrend, while a recovery above the recent highs near $155 would require a major catalyst, and the stock's low beta of 0.33 suggests it has been a defensive, low-volatility holding relative to the SPY, which matters for investors seeking stability but has not protected against the recent sector-specific selling pressure.
Beta
0.33
0.33x market volatility
Max Drawdown
-22.0%
Largest decline past year
52-Week Range
$104-$157
Price range past year
Annual Return
+15.1%
Cumulative gain past year
| Period | GILD Return | S&P 500 |
|---|---|---|
| 1m | -7.1% | -0.2% |
| 3m | -9.6% | +14.0% |
| 6m | -0.6% | +7.8% |
| 1y | +15.1% | +25.3% |
| ytd | +2.7% | +9.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GILD Fundamental Analysis
Revenue growth is modest but positive, with Q4 2025 revenue of $7.93 billion representing a 4.7% year-over-year increase, though this follows a volatile multi-quarter pattern including a strong Q3 2025 ($7.77 billion) and weaker prior quarters, indicating stable but not accelerating top-line growth. Segment data reveals the core HIV business remains the dominant driver with $5.8 billion in sales, while newer oncology assets like Cell Therapy ($627 million) and Trodelvy ($383 million) are contributing meaningfully, though Veklury (COVID-19 treatment) sales have dwindled to $211 million. The company is solidly profitable with Q4 2025 net income of $2.18 billion and a robust gross margin of 86.84%, though profitability has been inconsistent quarter-to-quarter, as seen in Q3 2025's net income of $3.05 billion and gross margin of 79.80%, reflecting product mix and one-time items; the trailing twelve-month net margin is a healthy 28.90%. The balance sheet is leveraged but manageable, with a debt-to-equity ratio of 1.08 and a strong current ratio of 1.68, while the company generates substantial cash flow, evidenced by TTM free cash flow of $9.46 billion and an ROE of 37.49%, indicating it can fund its acquisition-heavy strategy internally and still return capital to shareholders.
Quarterly Revenue
$7.9B
2025-12
Revenue YoY Growth
+0.04%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$9.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GILD Overvalued?
Given the company's consistent profitability, the primary valuation metric is the P/E ratio. The trailing P/E is 17.94x, while the forward P/E is lower at 12.80x, indicating the market expects earnings growth, which aligns with analyst EPS estimates rising from a trailing $0.06 to a forward $13.14. Compared to sector averages, Gilead's trailing P/E of 17.94x and forward P/E of 12.80x are difficult to benchmark precisely without a provided industry average, but the forward multiple suggests a reasonable valuation if growth materializes. Historically, the stock's current trailing P/E of 17.94x is below its own recent peak of 26.54x seen in Q1 2025 and is near the middle of its multi-year range, which includes a low of -5.45x during a loss-making quarter in early 2024, suggesting the current multiple prices in stable earnings without excessive optimism.
PE
17.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -5x~982x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
12.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Gilead's primary financial risk stems from the high cost and integration challenges of its aggressive M&A strategy, exemplified by the $7.8 billion Arcellx and $3.15 billion Tubulis deals, which pressure the balance sheet despite a manageable debt-to-equity of 1.08. Operationally, profitability is inconsistent, with quarterly net income swinging from $3.05 billion to -$4.17 billion over the past two years, and the company remains heavily dependent on its HIV franchise for 73% of Q4 2025 revenue, creating vulnerability to pricing or competitive pressures. While TTM free cash flow of $9.46 billion is strong, a significant portion is being allocated to acquisitions rather than returned to shareholders, with the dividend yield at a modest 2.62%.
Market & Competitive Risks: The stock faces significant valuation compression risk after its sharp 9.80% three-month decline, now trading 21% below its 52-week high. Its low beta of 0.33 has not provided protection during this sector-specific sell-off. Competitively, the core HIV market is mature, and the oncology pipeline build-out faces intense competition and clinical trial risks, as seen with the terminated Trodelvy-Keytruda lung cancer study. Regulatory and macro risks include potential drug pricing pressures and the impact of new policies like the 100% drug tariffs mentioned in recent news, though Gilead's domestic manufacturing may offer some insulation.
Worst-Case Scenario: The most damaging scenario would involve a combination of failed integration of major acquisitions, further clinical setbacks in key oncology assets like Trodelvy or the newly acquired Arcellx therapy, and accelerated erosion in the core HIV business due to competition or pricing. This could trigger multiple analyst downgrades, a derating of the forward P/E multiple, and a flight of patient capital. The realistic downside could see the stock re-testing its 52-week low of $104.46, representing a potential loss of approximately -16% from the current price of $123.76. A breach of that support could lead to further declines towards the $100 psychological level, aligning with a max drawdown historically around -22%.
FAQ
The key risks are, in order of severity: 1) Execution/Integration Risk: The multi-billion dollar acquisitions of Arcellx and Tubulis carry high costs and integration challenges without near-term profit contribution. 2) Pipeline/Clinical Risk: Recent termination of the Trodelvy-Keytruda lung cancer trial highlights the high failure rate in drug development, which could delay the oncology growth narrative. 3) Business Concentration Risk: Approximately 73% of Q4 2025 revenue came from the mature HIV segment, creating vulnerability. 4) Technical/Momentum Risk: The stock is in a pronounced downtrend, having underperformed the SPY by 24.94 percentage points over three months, which can become a self-fulfilling prophecy.
The 12-month forecast for GILD is a range-bound outlook with a base case target of $130-$150 (60% probability). This assumes steady execution, meeting the $13.14 EPS consensus, and no major pipeline setbacks. The bull case (25% probability) targets $157-$170 on successful acquisition integration and pipeline catalysts, while the bear case (15% probability) sees a drop to $104-$120 on further clinical failures or disappointing growth. The most likely scenario is the base case, as the market awaits concrete evidence that the company's expensive strategic pivot will pay off.
GILD appears fairly valued relative to its near-term prospects. Its forward P/E of 12.80x is a discount to its trailing P/E of 17.94x, reflecting expected EPS growth to $13.14. This multiple prices in the company's stable HIV cash flows but also the significant execution risk and costs associated with its oncology transformation. Compared to its own historical P/E range (which included a low of -5.45x), the current multiple is reasonable. The market is paying a fair price for a company in transition, not a premium for assured growth.
GILD is a good buy for a specific type of investor: those with a long-term horizon who are comfortable with a 'show me' story. The stock offers an attractive forward P/E of 12.80x, a 2.62% dividend yield, and is backed by unanimous analyst Buy ratings. However, its recent 9.80% three-month decline and high dependence on M&A for growth introduce significant near-term risk. It is a good buy for value-oriented investors seeking a defensive, cash-generative healthcare stock, but not for those seeking short-term momentum or pure growth.
GILD is unequivocally suitable for long-term investment, with a suggested minimum holding period of 3-5 years. Its low beta of 0.33 indicates low short-term volatility relative to the market, but its current strategy is a multi-year transformation. The value of its recent oncology acquisitions is not expected to materially impact earnings until 2028 or later. Short-term traders face headwinds from the stock's negative momentum and lack of immediate catalysts. Long-term investors can collect the dividend while waiting for the oncology pipeline to mature, provided they have the patience for the journey.